Kimberly-Clark Corporation (KMB) Dividend Profile

Kimberly-Clark makes the diapers, tissues, and toilet paper that a quarter of the world's population uses every day — Huggies, Kleenex, Cottonelle, Scott, Kotex, Depend — and it has paid a quarterly dividend without a miss since 1935. The January 2026 raise was the 54th in a row, which puts KMB comfortably on the dividend kings list. The next chapter is bigger than anything in that history: a $48.7 billion deal to buy Kenvue, the maker of Tylenol, Band-Aid, and Listerine, expected to close by the end of 2026.

KMB Dividend at a Glance

Current yield, annual dividend, and the exact streak length are shown live in the stats bar above.

Kimberly-Clark Dividend History: The Milestones

Why the Streak Has Lasted This Long

Products nobody stops buying

Diapers, toilet paper, feminine care, and adult incontinence products are about as non-discretionary as consumer goods get. Kimberly-Clark holds a No. 1 or No. 2 share position in roughly 70 countries and sells in more than 175, so a weak quarter in one market rarely dents the whole. That demand profile carried the payout through 2008 and 2020 without a wobble.

A margin machine, not a volume story

Sales barely grow — 2025 organic growth was 1.7%, and the first half of 2026 came in at 1.2% — but productivity does. The Powering Care plan launched in March 2024 targets more than $3 billion of gross productivity savings, and the results show up in the numbers: adjusted gross margin hit 38.8% in the second quarter of 2026, up 190 basis points in a year, and adjusted EPS from continuing operations rose 10.4%. Cost discipline, not price hikes, is what has funded the last few raises.

A portfolio that keeps getting pruned

Kimberly-Clark exited its US private-label diaper business, and in July 2026 it moved its international tissue and professional operations into Arbex, a joint venture in which Suzano owns 51% and Kimberly-Clark keeps 49%. What's left is a higher-margin personal-care company — and the Kenvue deal doubles down on that direction, adding a consumer-health portfolio with roughly $32 billion of combined revenue and about $7 billion of adjusted EBITDA.

What Could Break the Streak

Kimberly-Clark's risks are more concrete than most Dividend Kings' right now:

• The Kenvue integration. A $48.7 billion cash-and-stock deal is a different scale of bet from anything in the company's past. Management targets $2.1 billion of run-rate synergies but expects $2.5 billion of cash costs to get there. If the synergies slip, the debt doesn't.
• A leveraged balance sheet. The company is financing the cash portion with new debt plus the Arbex proceeds it once earmarked for buybacks. Its target is roughly 2x EBITDA within 24 months of closing, and until then share repurchases are limited to offsetting dilution. The dividend is the shareholder return that remains.
• A payout ratio with little slack. At roughly two-thirds of adjusted earnings, the 1.6% raise in 2026 was barely a raise at all — a sign of how carefully cash is being rationed.
• Private label and pulp. Store-brand diapers and tissue are the permanent competitor, and cellulose fiber is the primary raw material for nearly everything Kimberly-Clark sells, so a pulp price spike hits margins directly.
• Flat volumes. Second-quarter 2026 organic sales were roughly flat. A business growing at 1–2% has to earn every raise through cost cuts.

The realistic downside: a few years of token 1–2% raises while the Kenvue debt is paid down. An outright cut would require the integration to go badly wrong — possible, but a 92-year payment record argues against it.

What $10,000 of KMB Pays You

The income callout above shows what a $10,000 position generates at today's yield — paid in January, April, July, and October. Two things shape the number from there:

1. The raises are small for now. Expect low-single-digit increases until leverage is back near 2x; the higher starting yield is your compensation for waiting.
2. Reinvestment does more work at a higher yield. Routing payments through a DRIP buys more shares per quarter than a low-yield grower would — model a decade of it with our yield-on-cost calculator.

How KMB Fits in a Dividend Portfolio

Kimberly-Clark is a higher-yield staples holding with an event attached: defensive products, a King-length streak, and a transformative deal that will define the next five years.

• Role: the income end of the yield vs. growth spectrum — more yield today, slower growth than peers
• Pairs well with: steadier, lower-yield staples such as Procter & Gamble or Colgate-Palmolive, which carry less balance-sheet risk
• Watch annually: the late-January raise announcement, the Kenvue closing and synergy updates, and the leverage ratio's path back toward 2x

Every major broker offers KMB with fractional shares and free reinvestment — compare platforms, or see its peers among the 25-year-plus streaks on the dividend aristocrats list.